Search results
Results from the WOW.Com Content Network
At the beginning of 2011, DePuy Orthopaedics said they were phasing out the ASR Hip Implant because of declining sales, but never mentioned the high failure rate data from an Australian implant registry. In March 2011, The New York Times reported that DePuy issued its first warning to doctors and patients about the high early failure rate.
On August 24, 2010, DePuy, a subsidiary of American giant Johnson & Johnson, recalled its ASR (articular surface replacement) hip prostheses from the market. DePuy said the recall was due to unpublished National Joint Registry data showing a 12% revision rate for resurfacing at five years and an ASR XL revision rate of 13%.
Metallosis. Metallosis is the medical condition involving deposition and build-up of metal debris in the soft tissues of the body. [1] Metallosis has been known to occur when metallic components in medical implants, specifically joint replacements, abrade against one another. [1] Metallosis has also been observed in some patients either ...
Let's compare that to Johnson & Johnson's high-profile hip device recall. 37% of subsidiary DePuy's ASR hip implants, which J&J pulled in 2010, failed within five years, according to an internal ...
Johnson & Johnson and its DePuy Orthopaedics unit have agreed to pay $120 million to resolve deceptive marketing claims by several U.S. states. J&J, U.S. states settle hip implant claims for $120 ...
Columbus police and the Ohio Attorney General's office on Oct. 25 announced an indictment against Rebecca Auborn, a 33-year-old woman authorities say is a serial killer.. Here's what we know about ...
www .depuysynthes .com. DePuy Synthes ( / dəˈpjuː /) is a franchise of orthopaedic and neurosurgery companies. Acquired by Johnson & Johnson in 1998, its companies form part of the Johnson & Johnson Medical Devices group. DePuy develops and markets products under the Codman, DePuy Mitek, DePuy Orthopaedics and DePuy Spine brands.
In a letter to J&J's DePuy Orthopaedics, the FDA says it has learned that the company is marketing the TruMatch without the required marketing clearance or approval and in violation of the Federal ...